Antibodies against HER3
The invention relates to antibodies against HER3 and their use in the treatment of cancer.
1. An anti-HER3 antibody comprising:
(i) a heavy chain wherein the variable domain comprises:
SEQ ID NO: 1 for H-CDR1,
SEQ ID NO: 2 for H-CDR2, and
SEQ ID NO: 3 for H-CDR3; and
(ii) a light chain in which the variable domain comprises:
L-CDR1 selected from the group consisting of SEQ ID NO:4, SEQ ID NO: 11, SEQ ID NO: 18, SEQ ID NO: 25 and SEQ ID NO: 29,
L-CDR2 selected from the group consisting of SEQ ID NO:5, SEQ ID NO: 12 and SEQ ID NO: 19 and
L-CDR3 selected from the group consisting of SEQ ID NO:6, SEQ ID NO: 13, SEQ ID NO: 20 and SEQ ID NO: 26.
2. The antibody according to claim 1 , wherein the heavy chain variable domain has the amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 14 and SEQ ID NO: 21.
3. The antibody according to claim 1 wherein the light chain variable domain has an amino acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 22, SEQ ID NO: 27 and SEQ ID NO: 30.
4. The antibody according to claim 1 wherein said antibody is selected from the group consisting of:
an antibody comprising the heavy chain variable domain having the amino acid sequence set forth as SEQ ID NO: 7, and the light chain variable domain having the amino acid sequence selected from the group consisting of SEQ ID NO: 8 and SEQ ID NO: 30,
an antibody comprising the heavy chain variable domain having the amino acid sequence set forth as SEQ ID NO: 14, and the light chain variable domain having the amino acid sequence selected from the group consisting of SEQ ID NO: 15 and SEQ ID NO: 27 and
an antibody comprising the heavy chain variable domain having the amino acid sequence set forth as SEQ ID NO: 21, and the light chain variable domain having the amino acid sequence selected from the group consisting of SEQ ID NO: 22.
5. The antibody according to claim 1 wherein said antibody is a human antibody.
6. The antibody according to claim 1 wherein said antibody is an antibody fragment selected from the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.
7. A nucleic acid comprising a sequence encoding at least the heavy chain and the light chain of the antibody according to claim 1 .
8. A vector comprising a nucleic acid according to claim 7 .
9. A host cell comprising a nucleic acid according to claim 7 .
10. A host cell comprising a vector according to claim 8 .
11. A pharmaceutical composition comprising an antibody according to claim 1 and a pharmaceutically acceptable carrier.
12. A method of treating cancer in a subject in need thereof comprising
administering to said subject a therapeutically effective amount of the antibody of claim 1 .